These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38187379)

  • 21. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
    Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
    BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis.
    Chara L; Sánchez-Atrio A; Pérez A; Cuende E; Albarrán F; Turrión A; Chevarria J; Sánchez MA; Monserrat J; de la Hera A; Prieto A; Sanz I; Diaz D; Alvarez-Mon M
    Arthritis Res Ther; 2012 Jul; 14(4):R175. PubMed ID: 22838733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis.
    Thomson TM; Lescarbeau RM; Drubin DA; Laifenfeld D; de Graaf D; Fryburg DA; Littman B; Deehan R; Van Hooser A
    BMC Med Genomics; 2015 Jun; 8():26. PubMed ID: 26036272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin B-6 Status Correlates with Disease Activity in Rheumatoid Arthritis Patients During Treatment with TNFα Inhibitors.
    Sande JS; Ulvik A; Midttun Ø; Ueland PM; Hammer HB; Valen M; Apalset EM; Gjesdal CG
    J Nutr; 2019 May; 149(5):770-775. PubMed ID: 31050750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA.
    Chen PK; Lan JL; Chen YM; Chen HH; Chang SH; Chung CM; Rutt NH; Tan TM; Mamat RNR; Anuar ND; Blackburn JM; Chen DY
    J Immunol Res; 2021; 2021():6656121. PubMed ID: 33763493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
    Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A
    Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
    Choi IY; Gerlag DM; Herenius MJ; Thurlings RM; Wijbrandts CA; Foell D; Vogl T; Roth J; Tak PP; Holzinger D
    Ann Rheum Dis; 2015 Mar; 74(3):499-505. PubMed ID: 24297376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study.
    Hirata S; Li W; Defranoux N; Cavet G; Bolce R; Yamaoka K; Saito K; Tanaka Y
    Mod Rheumatol; 2015 May; 25(3):344-9. PubMed ID: 25295918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.
    Furst DE; Kavanaugh A; Florentinus S; Kupper H; Karunaratne M; Birbara CA
    Rheumatology (Oxford); 2015 Dec; 54(12):2188-97. PubMed ID: 26199453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tumour necrosis factor-alpha response associated with combined CD226 and HLA-DRB1[*]0404 haplotype in rheumatoid arthritis.
    Gibson DS; McGeough CM; Watterson S; Blayney J; Wright GD; Pendleton A; Gardiner P; Small D; Eakin AJ; Ahmed T; Murray HA; Latten MJ; Crockard MA; Lamont JV; Zhang SD; Bjourson AJ
    Clin Exp Rheumatol; 2021; 39(2):385-392. PubMed ID: 33427622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble CD206 plasma levels in rheumatoid arthritis reflect decrease in disease activity.
    Heftdal LD; Stengaard-Pedersen K; Ørnbjerg LM; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Deleuran B; Møller HJ; Greisen SR
    Scand J Clin Lab Invest; 2017 Sep; 77(5):385-389. PubMed ID: 28598681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
    Jani M; Chinoy H; Warren RB; Griffiths CE; Plant D; Fu B; Morgan AW; Wilson AG; Isaacs JD; Hyrich K; Barton A;
    Arthritis Rheumatol; 2015 May; 67(8):2011-9. PubMed ID: 26109489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Periodontal and serum protein profiles in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitor adalimumab.
    Kobayashi T; Yokoyama T; Ito S; Kobayashi D; Yamagata A; Okada M; Oofusa K; Narita I; Murasawa A; Nakazono K; Yoshie H
    J Periodontol; 2014 Nov; 85(11):1480-8. PubMed ID: 24857321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells.
    Julià A; Barceló M; Erra A; Palacio C; Marsal S
    Pharmacogenomics; 2009 Oct; 10(10):1697-708. PubMed ID: 19842941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship Between Adalimumab Concentrations, Antidrug Antibodies, and Disease Activity in Rheumatoid Arthritis: A Cross-Sectional Observational Study.
    Stamp LK; Keating P; Frampton C; Barclay ML; Fanning N; Millier M; Hessian PA; O'Donnell JL
    J Rheumatol; 2024 Mar; 51(3):242-249. PubMed ID: 38224989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
    Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
    Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity.
    Lamers-Karnebeek FBG; Jacobs JWG; Radstake TRDJ; van Riel PLCM; Jansen TL
    Rheumatology (Oxford); 2019 Mar; 58(3):427-431. PubMed ID: 30383251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis.
    Dávila-Fajardo CL; van der Straaten T; Baak-Pablo R; Medarde Caballero C; Cabeza Barrera J; Huizinga TW; Guchelaar HJ; Swen JJ
    Pharmacogenomics; 2015; 16(4):373-81. PubMed ID: 25823785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis.
    Yoosuf N; Maciejewski M; Ziemek D; Jelinsky SA; Folkersen L; Müller M; Sahlström P; Vivar N; Catrina A; Berg L; Klareskog L; Padyukov L; Brynedal B
    Rheumatology (Oxford); 2022 Apr; 61(4):1680-1689. PubMed ID: 34175943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.